Endo Pharmaceuticals Receives Subpoena From U.S. Department of Health and Human Services

CHADDS FORD, PA -- (MARKET WIRE) -- January 17, 2007 -- Endo Pharmaceuticals Inc., a wholly owned
subsidiary of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), announced
that it received a subpoena today from the U.S. Department of Health and
Human Services, Office of Inspector General, requesting documents from 1999
to the present regarding the company's sales and promotional practices
relating to Lidoderm® (lidocaine patch 5%). The company intends to
cooperate with this request. The subpoena requests documents generally
related to the company's knowledge of the use of Lidoderm® for
non-indicated uses by physicians.

"Endo has been and will continue to be firmly committed to promoting
Lidoderm® and all of Endo's marketed products responsibly and
appropriately within their currently approved indications," said
Peter A. Lankau, President and Chief Executive Officer. "We have a strong
ethics and compliance program. To that end, we routinely conduct extensive
training for our employees to reinforce the importance of promotional
practices that are within the FDA-approved indication."

Lidoderm® is a topical analgesic patch approved by the U.S. Food and Drug
Administration in 1999 to treat the pain associated with post-herpetic
neuralgia (PHN), a chronic condition resulting from nerve damage caused by
shingles.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended, that are based on management's
beliefs and assumptions, current expectations, estimates and projections.
Statements that are not historical facts, including statements which are
preceded by, followed by, or that include, the words "believes,"
"anticipates," "plans," "expects" or similar expressions and statements are
forward-looking statements. Endo's estimated or anticipated future results,
product performance or other non-historical facts are forward-looking and
reflect Endo's current perspective on existing trends and information. Many
of the factors that will determine the Company's future results are beyond
the ability of the Company to control or predict. These statements are
subject to risks and uncertainties and, therefore, actual results may
differ materially from those expressed or implied by these forward-looking
statements. The reader should not rely on any forward-looking statement.
The Company undertakes no obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. Several important factors, in addition to the specific factors
discussed in connection with these forward-looking statements individually,
could affect the future results of Endo and could cause those results to
differ materially from those expressed in the forward-looking statements
contained in this press release. Important factors that may affect future
results include, but are not limited to: market acceptance of the Company's
products and the impact of competitive products and pricing; dependence on
sole source suppliers; the success of the Company's product development
activities and the timeliness with which regulatory authorizations and
product launches may be achieved; successful compliance with extensive,
costly, complex and evolving governmental regulations and restrictions; the
availability on commercially reasonable terms of raw materials and other
third party manufactured products; exposure to product liability and other
lawsuits and contingencies; dependence on third party suppliers,
distributors and collaboration partners; the ability to timely and cost
effectively integrate acquisitions; uncertainty associated with
pre-clinical studies and clinical trials and regulatory approval;
uncertainty of market acceptance of new products; the difficulty of
predicting FDA approvals; risks with respect to technology and product
development; the effect of competing products and prices; uncertainties
regarding intellectual property protection; uncertainties as to the outcome
of litigation; changes in operating results; impact of competitive products
and pricing; product development; changes in laws and regulations; customer
demand; possible future litigation; availability of future financing and
reimbursement policies of government and private health insurers and
others; and other risks and uncertainties detailed in Endo's filings with
the Securities and Exchange Commission, including its Registration
Statement on Form S-3 filed with the SEC on March 21, 2006. Readers should
evaluate any statement in light of these important factors.